Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Psychiatric comorbidity in individuals with bullous pemphigoid and all bullous disorders in the Danish national registers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Detection of illness worry in the general population: A specific item on illness rumination improves the Whiteley Index

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Duffy-null genotype and risk of infection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association between Mental Disorders and Subsequent Medical Conditions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering skin disease that takes a profound physical and mental toll on those affected. The aim of the study was to investigate the bidirectional association between BP and all bullous disorders (ABD) with a broad array of psychiatric disorders, exploring the influence of prescribed medications.

METHODS: This nationwide, register-based cohort study encompassed 6,470,450 individuals born in Denmark and alive from 1994 to 2016. The hazard ratios (HRs) of a subsequent psychiatric disorder in patients with BP/ABD and the reverse exposure and outcome were evaluated.

RESULTS: Several psychiatric disorders were associated with increased risk of subsequent BP (4.18-fold for intellectual disorders, 2.32-fold for substance use disorders, 2.01-fold for schizophrenia and personality disorders, 1.92-1.85-1.49-fold increased risk for organic disorders, neurotic and mood disorders), independent of psychiatric medications. The association between BP and subsequent psychiatric disorders was not significant after adjusting for BP medications, except for organic disorders (HR 1.27, CI 1.04-1.54). Similar results emerged with ABD.

CONCLUSION: Psychiatric disorders increase the risk of a subsequent diagnosis of BP/ABD independent of medications, whereas medications used for the treatment of BP/ABD appear to account for the subsequent onset of psychiatric disorders. Clinically, an integrated approach attending to both dermatological and psychiatric symptoms is recommended, and dermatologists should remain vigilant for early symptoms of psychiatric disorders to decrease mental health comorbidity.

OriginalsprogEngelsk
TidsskriftBMC Psychiatry
Vol/bind20
Udgave nummer1
Sider (fra-til)411
ISSN1471-244X
DOI
StatusUdgivet - 20 aug. 2020

ID: 60906407